Active Tuberculosis Is Characterized by Highly Differentiated Effector Memory Th1 Cells
Overview
Authors
Affiliations
Despite advances in diagnosing latent infection (LTBI), we still lack a diagnostic test that differentiates LTBI from active tuberculosis (TB) or predicts the risk of progression to active disease. One reason for the absence of such a test may be the failure of current assays to capture the dynamic complexities of the immune responses associated with various stages of TB, since these assays measure only a single parameter (release of IFN-γ) and rely on prolonged (overnight) T cell stimulation. We describe a novel, semi-automated RNA flow cytometry assay to determine whether immunological differences can be identified between LTBI and active TB. We analyzed antigen-induced expression of Th1 cytokine mRNA after short (2- and 6-h) stimulation with antigen, in the context of memory T cell immunophenotyping. IFNG and TNFA mRNA induction was detectable in CD4+ T cells after only 2 h of stimulation. Moreover, IFNG- and TNFA-expressing CD4+ T cells (Th1 cells) were more frequent in active TB than in LTBI, a difference that is undetectable with conventional, protein-based cytokine assays. We also found that active TB was associated with higher ratios of effector memory to central memory Th1 cells than LTBI. This effector memory phenotype of active TB was associated with increased T cell differentiation, as defined by loss of the CD27 marker, but not with T cell exhaustion, as determined by PD-1 abundance. These results indicate that single-cell-based, mRNA measurements may help identify time-dependent, quantitative differences in T cell functional status between latent infection and active tuberculosis.
Izumida M, Jobe H, Coker E, Barry A, Rashid M, Manneh I Front Immunol. 2024; 15:1422700.
PMID: 39257584 PMC: 11384583. DOI: 10.3389/fimmu.2024.1422700.
Tuberculosis Vaccines and T Cell Immune Memory.
Li F, Dang W, Du Y, Xu X, He P, Zhou Y Vaccines (Basel). 2024; 12(5).
PMID: 38793734 PMC: 11125691. DOI: 10.3390/vaccines12050483.
Zhao X, Ju B, Xiu N, Sun X, Meng F Front Immunol. 2024; 15:1339971.
PMID: 38426096 PMC: 10902444. DOI: 10.3389/fimmu.2024.1339971.
Immunogenicity and efficacy of an oral live-attenuated vaccine for bovine Johne's disease.
Eshraghisamani R, Facciuolo A, Harman-McKenna V, Illanes O, De Buck J Front Immunol. 2024; 14:1307621.
PMID: 38283338 PMC: 10810994. DOI: 10.3389/fimmu.2023.1307621.
Panda S, Morgan J, Cheng C, Saito M, Gilman R, Ciobanu N Nat Commun. 2024; 15(1):765.
PMID: 38278794 PMC: 10817963. DOI: 10.1038/s41467-024-45058-9.